Muhammed Celik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Muhammed Celik has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Anne-Kristin Schaefer
Department of Cardiac Surgery, Medical University of Vienna, 1090 Vienna, Austria
1 shared publication - Barbara Karner
Department of Cardiac and Thoracic Aortic Surgery, Medical University of Vienna, 1090 Vienna, Austria
1 shared publication - Christiane Marko
Department of Cardiac and Aortic Thoracic Surgery, Medical University Vienna, 1090 Vienna, Austria
1 shared publication - Daniel Zimpfer
Department of Cardiac and Thoracic Aortic Surgery, Medical University of Vienna, 1090 Vienna, Austria
1 shared publication - Hebe Al Asadi
Department of Cardiac and Thoracic Aortic Surgery, Medical University of Vienna, 1090 Vienna, Austria
1 shared publication - Julia Riebandt
Department of Cardiac Surgery, Medical University of Vienna, 1090 Vienna, Austria
1 shared publication
Latest Publications
- Open Access
- 2 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (17) , 6193
Prognostic Significance of Albumin in Modern Left Ventricular Assist Device Therapy: Relevance in the HeartMate 3 Era?
Background/Objectives: Preoperative hypoalbuminemia is a known risk factor for adverse outcomes in cardiac surgery, but its role in patients undergoing HeartMate 3 (HM3) left ventricular assist device (LVAD) implantation is unclear. This study evaluated the association between albumin levels and postoperative outcomes, aiming to define a clinically meaningful cut-off for risk stratification. Methods: We retrospectively analyzed 205 adult patients who underwent HM3 implantation at a single center from June 2014 to December 2023. Receiver operating characteristic (ROC) analysis identified an optimal pre-implant albumin cut-off of p = 0.004) and bleeding (38.1% vs. 23.2%, p = 0.012). Freedom from HRAEs was significantly lower in the hypoalbuminemia group (45.2% vs. 69.8%, p < 0.001) and competing risk-adjusted cumulative incidence for HRAE was higher, but did not reach statistical significance (p = 0.11), one-year HRAE-free survival was also reduced (68.5% vs. 85.7%, p = 0.03). In multivariable analysis, low albumin (HR 0.56, 95% CI 0.33–0.93, p = 0.026) and temporary right ventricular assist device (RVAD) support (HR 3.32, 95% CI 2.05–5.39, p < 0.001) were independent predictors of HRAEs. Conclusions: Low preoperative albumin is independently associated with increased HRAEs and reduced one-year survival after HM3 implantation. Compared with the traditional 35 g/L threshold, the ROC-derived 32 g/L cut-off offered superior balance between sensitivity and specificity, underscoring its clinical utility. Albumin may serve as a simple, pragmatic, and cost-effective biomarker for preoperative risk assessment and optimization.
- 2 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (17) , 6193
Open AccessPrognostic Significance of Albumin in Modern Left Ventricular Assist Device Therapy: Relevance in the HeartMate 3 Era?
Background/Objectives: Preoperative hypoalbuminemia is a known risk factor for adverse outcomes in cardiac surgery, but its role in patients undergoing HeartMate 3 (HM3) left ventricular assist device (LVAD) implantation is unclear. This study evaluated the association between albumin levels and postoperative outcomes, aiming to define a clinically meaningful cut-off for risk stratification. Methods: We retrospectively analyzed 205 adult patients who underwent HM3 implantation at a single center from June 2014 to December 2023. Receiver operating characteristic (ROC) analysis identified an optimal pre-implant albumin cut-off of p = 0.004) and bleeding (38.1% vs. 23.2%, p = 0.012). Freedom from HRAEs was significantly lower in the hypoalbuminemia group (45.2% vs. 69.8%, p < 0.001) and competing risk-adjusted cumulative incidence for HRAE was higher, but did not reach statistical significance (p = 0.11), one-year HRAE-free survival was also reduced (68.5% vs. 85.7%, p = 0.03). In multivariable analysis, low albumin (HR 0.56, 95% CI 0.33–0.93, p = 0.026) and temporary right ventricular assist device (RVAD) support (HR 3.32, 95% CI 2.05–5.39, p < 0.001) were independent predictors of HRAEs. Conclusions: Low preoperative albumin is independently associated with increased HRAEs and reduced one-year survival after HM3 implantation. Compared with the traditional 35 g/L threshold, the ROC-derived 32 g/L cut-off offered superior balance between sensitivity and specificity, underscoring its clinical utility. Albumin may serve as a simple, pragmatic, and cost-effective biomarker for preoperative risk assessment and optimization.